Abstract. Thrombin-induced accumulation of phosphatidylinositol 3,4-bisphosphate (Ptdlns(3,4)P2) but not of PtdIns(3, 4, 5, )P3 is strongly correlated with the relocation to the cytoskeleton of 29 % of the p85o~ regulatory subunit of phosphoinositide 3-kinase (Ptdlns 3-kinase) and is accompanied by a significant increase in Ptdlns 3-kinase activity in this subcellular fraction. Actually, Ptdlns(3,4)P2 accumulation and Ptdlns 3-kinase, pp60 ~-s'~, and p125 eA~ translocations as well as aggregation were concomitant events occurring with a distinct lag after actin polymerization. The accumulation of Ptdlns(3,4)P2 and the relocalization of Ptdlns 3-kinase to the cytoskeleton were both dependent on tyrosine phosphorylation, integrin signaling, and aggregation. Furthermore, although p85o~ was detected in anti-phosphotyrosine immunoprecipitates obtained from the cytoskeleton of thrombin-activated platelets, we failed to demonstrate tyrosine phosphorylation of cytoskeletal p85a. Tyrphostin treatment clearly reduced its presence in this subcellular fraction, suggesting a physical interaction of p85et with a phosphotyrosyl protein. These data led us to investigate the proteins that are able to interact with Ptdlns 3-kinase in the cytoskeleton. We found an association of this enzyme with actin filaments: this interaction was spontaneously restored after one cycle of actin depolymerization-repolymerization in vitro. This association with F-actin appeared to be at least partly indirect, since we demonstrated a thrombin-dependent interaction of p85tx with a proline-rich sequence of the tyrosine-phosphorylated cytoskeletal focal adhesion kinase, p125 rAK. In addition, we show that Ptdlns 3-kinase is significantly activated by the p125 rAK proline-rich sequence binding to the src homology 3 domain of p85a subunit. This interaction may represent a new mechanism for Ptdlns 3-kinase activation at very specific areas of the cell and indicates that the focal contact-like areas linked to the actin filaments play a critical role in signaling events that occur upon ligand engagement of o~ro/~3 integrin and platelet aggregation evoked by thrombin.
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T HE accumulation of phosphatidylinositol 3,4-bisphosphate (Ptdlns(3,4)P2) m and Ptdlns (3, 4, 5) P3 in thrombin-stimulated human platelets is now well established (16, 24, 38, 41) and seems to be regulated differently (38) . However, the exact mechanism of activation of phosphoinositide 3-kinase (Ptdlns 3-kinase) in these ceils is still obscure. The small G-protein rho (51) , G-protein/33, subunit (44) protein kinase C (PKC) (26) , Ca 2+ (38) , as well as tyrosine phosphorylation (19) may contribute to its activa-tion. Possible ways of stimulation in other models also include physical association with specific proteins via the src homology 2 (SH2) domains or the proline-rich regions of the p85 subunit. This results in a conformational change of p85 that appears to be transmitted to the catalytic subunit (pll0) as an activation signal (34, 37) . Since Ptdlns 3-kinase has been found to be associated with activated PDGF receptor (10) or pp60 v-s' (14) , with a potentially very important role in mitogenesis (46) or oncogenic transformation (43) , respectively, great interest has been elicited by its products (i.e., D3-phosphorylated phosphoinositides). Although their precise function is still unknown, these phospholipids have been suggested to play a role as second messengers activating downstream signaling enzymes like PKCg" isoform (29) . Moreover, based on the homology of pll0 with Saccharomyces cerevisiae protein Vps34p, Ptdlns 3-kinase and/ or its products have been recently suggested to play a role in intracellular sorting and down-regulating processes involving vesicle formation and targeting to the endosomal compartment (31) . Another hypothesis is a possible role of Ptdlns 3-kinase in regulating the polymerization and the organization of actin, as suggested by the simultaneous appearance of PtdIns (3, 4, 5) P3 and actin polymerization of N-formyl peptide-stimulated human neutrophils (9) .
In human platelets stimulated by thrombin, PtdIns(3,4,5)P3 production occurs very rapidly (38) , whereas the accumulation of PtdIns (3, 4) P2 is a late event dependent upon fibrinogen binding to the integrin receptor O~nb//~3 (38, 41, 42) and partly requires tyrosine phosphorylations (19, 48) . Its production may be due to Ptdins (3, 4, 5) P3 degradation by a 5-phosphatase (40) , to the effect of a Ptdlns(3)P 4-kinase (47) , or to the direct action of Ptdins 3-kinase on Ptdins(4)P. Since accumulations of Ptdins(3,4)P2 and PtdIns (3, 4, 5) P3 display different sensitivities to Ca 2+, integrin mobilization (38) , and tyrosine phosphorylation (48) , it is more likely that PtdIns (3, 4) P2 synthesis in platelet is due to the action of a 4-kinase on PtdIns(3)P or to the action of PtdIns 3-kinase on Ptdlns(4)P, both of which would involve Ptdins 3-kinase. However, we and others have previously observed a translocation of PtdIns 3-kinase to the cytoskeleton of thrombinactivated platelets 08, 50). It is noteworthy that an association of PtdIns 3-kinase with the eytoskeleton has also been reported in other cells (32) . In human platelets, thrombin stimulation leads to a dramatic reorganization of the eytoskeleton (15) , which is possibly triggered in part by interaction of intetrin receptors with their ligands (21) . Interestingly, several proteins involved in signal transduction are found relocated to the cytoskeleton of thrombin-activated platelets; among these are various enzymes of phosphoinositide metabolism (18) and pp60 ~-"~ (7, 18) . This cellular protooncogene tyrosine kinase has been described to interact with Ptdins 3-kinase in different cell types (34) . pp60 "~ is constitutively present in large amounts in platelets and may be responsible for the phosphorylation and the regulation of different enzymes (8) . A potential role of this tyrosine kinase in the integrin-dependent part of PtdIns 3-kinase activation in platelets is thus conceivable. In this model, thrombine induces the activation of pp60'-'% which is then translocated to the cytoskeleton after oerd/~3 integrin receptor mobilization and aggregation (7) . However, other non-receptor tyrosine kinases whose activation is related to integrin signaling and eytoskeleton reorganization, like focal adhesion kinase (p125~r), may also play crucial roles in platelet activation (27) .
Taken together, these observations point to a potentially important and dynamic function of the cytoskeleton in various signal transduction pathways. Therefore, to determine its possible functional relationships, we decided to study in detail the translocation of PtdIns 3-kinase to the platelet cytoskeleton during thrombin activation. Interestingly, kinetic studies revealed a strong correlation between the relocation of PtdIns 3-kinase and the accumulation of PtdIns(3,4)P2. Since these events were dependent on both aggregation and otm//~3 integrin receptor engagement, our approach was to ask whether PtdIns 3-kinase activation and translocation were related to tyrosine phosphorylation promoted by integrin signaling. The data obtained indicated an important role for the integrin-dependent tyrosine kinase activation; however, cytoskeletal p85o~ was not tyrosine phosphorylated. This observation led us to investigate the proteins that may interact with PtdIns 3-kinase in the cytoskeleton of activated platelets. We found that thrombin activation ofplatelets leads to the formation of multienzymatic complexes, including PtdIns 3-kinase and tyrosine-phosphorylated p125 ~c in areas tightly associated with the actin filament system corresponding to focal contact-like domains. Their formation appears to be dependent upon aggregation and is related to integrin-dependent tyrosine kinase activation. In investigating these associations further, we found that a proline-rich sequence of human p125 r~K (residues 706-711) directly bound to the SH3 domain of p85a. Interestingly, micromolar amounts of a peptide corresponding to the proline-rich region of p125 rAK (706-711) increased the specific activity of PtdIns-3 kinase. We therefore propose that this interaction may represent a new mechanism for PtdIns 3-kinase activation at very specific areas (i.e., focal contact points). The strong correlation observed between the formation of these focal adhesion-like domains and the accumulation of PtdIns(3,4)P2 in this model may help to elucidate its functionai relationships and emphasize the dynamic role of the cytoskeleton in signal transduction.
Materials and Methods

Antibodies and Fusion Proteins
The mouse anti-actin antibody was obtained from Amersham International (Buckinghamshire, UK). Mouse anti-p125 E°c, mouse anti-phosphotyrosine 41310, and rat anti-p85c~ antibodies came from Upstate Biotechnology Inc. (New York). A highly specific antibody against the p85a subunit was kindly provided by Dr. Wateriield (Ludwig Institute for Cancer Research, London). Sheep polyclonal antiserum against pp60 c-s'r was from Cambridge Research Biochemicals Inc. (Cambridge, UK). The mouse antiphosphotyrosine 4GI0 coupled to agarose, the GST-p85c~-SI-I2 (NH2) immobilized or not on agarose, and the anti-GST antibody were from TEBU (Santa Cruz Biotechnulogy, Inc., Santa Cruz, CA). GST-p85a-SH3 was from PharMingen (San Diego, CA).
Preparation and Activation of Platelets
Platelet concentrates provided by the local blood bank (Centre l~gional de Transfusion Sanguine de Toulouse) were used to prepare platelets as previously described (19) according to Ardlie et al. (2) . For inositoi lipid analysis, platelets were labeled with 0.3 rnCi/ml 32pi (Amersham International) during 60 rain in Ca2+-free Tyrode's buffer (pH 6.5, 0.2 mM EGTA) at 37°C. After a washing step in the same buffer minus EGTA, platelets were resnspended in Tyrode's buffer containing 2.5 mM CaC]2 (3 × 109 or 5 x l0 s cells per ml when the tetrapeptide RGDS was used) (42) . In some experiments, before the stimulation by human thrombin (Sigma Chemical Co., St. Louis, MO), platelets were preincubated for 5 rain in the presence of 100 /~M tyrphostin AG-213 (supplied by Dr. A. Levitzki, Hebrew University, Jerusalem, Israel) or for 15 s with 500 t~M RGDS (Sigma Chemical Co.). Activation by thrombin was performed with shaking. Aggregation was followed in parallel by turbidimetry using an aggregometer (Chronolog, Havertown, PA) (3 × 109 or 5 × l0 s cells per ml as indicated, 600 rpm.).
Lipid Extraction and Analysis
Reactions were stopped by addition of chloroform/methanol (vol/vol), and the lipids were extracted following a modified procedure of Bligh and Dyer (3) . Lipids were immediately deacylated and analyzed using an HPLC technique on a Parfisphere SAX column 0Vhatman International Ltd., UK) as previously described (41) .
Cytoskeleton Extraction
Reactions were stopped, and cytoskeleton was immediately isolated by adding 1 vol of ice-cold CSK buffer containing 100 mM Tris-HCl, pH 7.4, 20 mM EGTA, 2 mM Na3VO4, 2 ~g/ml aprotinin, 2 t~g/ml leupeptin, 1 mM PMSF (Sigma Chemical Co.), and 2% (vol/vol) Triton X-100 to control or activated platelet suspensions (33) . After a 10-rain incubation at 4°C, the cytoskeletai and Triton X-100-soluble fractions were separated by centrifugation (12,000 g, 10 rain, 4°C). For further use, cytoskeletons were washed as described by Grondin et al. (18) and subsequently resuspended in suitable buffers by sonication (20 kI-Iz for 2 × 10 s) using an ultrasonic cell disruptor.
Isolation of Polymerized Actin and the Actin-Binding Protein-Rich Fraction
Actin filaments were isolated as previously described by Payrastre et al. (32) . Briefly, cytoskeletons from resting or activated platelets were solubilized in 10 ml of buffer A containing 0.6 M KI, 100 mM Pipes, pH 6.5, 100 mM KC1, 10 t~g/mi leupeptin, 1 mM PMSE and 100 t~M Na3VO4 for 20 rain at 40C with gentle shaking and centrifuged at 40,000 g for 20 rain at 40C. The supernatant, containing actin, was dialyzed at 4°C for 3 h against a buffer containing 10 mM Pipes, pH 6.8, 1 mM EGTA, 2 mM MgCI2, 1 mM PMSE 2/~g/ml aprotinin, and 100 #M Na3VO4. Actin was then repolymerized, and this suspension was centrifuged at 12,000 g for 10 rain at 4"C. The pellet, corresponding to actin filaments and the actinbinding protein-rich fraction, was resuspended in 50 mM Tris-HCI (pH 7.3) and immediately used for the PtdIns 3-kinase assay or Western blotting.
Ptdlns 3-Kinase Assay
PtdIns 3-kinase activity was measured in a final volume of 100 t~l containing 50 mM Tris-HCl, pH 7.4, 1.5 mM DTT, 100 mM NaCl, 0.5 mM EDTA, 5 mM MgCl2, 5/zM ATE exogenous lipid vesicles (100 ~M phosphatidylinositol plus 200 ~M phosphatidylserine, prepared by sonication in 50 mM Tris-HCl, pH 7.4), and proteins from the different fractions. Reactions were started by adding 10 ILCi of [~/-32P]ATP (Amersham International) and were performed at 37"C with shaking for 10 rain. Reactions were stopped by adding a mixture of chloroform/methanol (vol/vol), and lipids were extracted and analyzed as previously described (41) .
Immunoprecipitation and Immunopurification
Cytoskeletons were resuspended in 1 ml ofa lysis buffer containing 40 mM Tris-HC1, pH 7.4, 100 mM NaCI, 100 mM NaF, 10 mM EDTA, 40 mM Na4P2OT, 2 mM Na3VO4, 2/~g/ml aprotinin, 2 /~g/ml leupeptin, 1 mM PMSF, 0.2% SDS, and 1% (vol/vol) Triton X-100. After sonication (20 kHz for 2 x 10 s), shaking for 20 min, and centrifugation (12,000 g for 10 min at 4"C), the soluble fraction was collected and subsequently precleared for 30 rain at 4°C with protein A-Sepharose CL-4B or protein G-Sepharose 4B fast flow, depending on the subclasses and the origin of the antibodies used (Sigma Immuno Chemicals). Precleared suspensions were then incubated for 120 rain at 4*C with the different antibodies: anti-phosphotyrosine antibody 4GI0 coupled to agarose, anti-p125 r~K antibody (dilution 1:200), or anti-p85ct antibody (dilution 1:200). After the first 60 rain, 50 t~l of 10% (wt/vol) protein A-or protein G-Sepharose resuspended in lysis buffer was added. The immunoprceipitates were then washed three times as described (19) . With anti-phosphotyrosine immunoprecipitates, the phosphotyrosyl proteins were eluted as previously described (19) .
Gel Electrophoresis and Western Blotting
Proteins were solubilized in electrophoresis sample buffer (100 mM Tris-HCI, pH 6.8, 15% (vol/vol) glycerol, 25 mM DTT, 3% SDS), boiled for 5 rain and separated on 7.5% SDS-PAGE. Proteins were then blotted onto nitrocellulose (Bio Pad Laboratories, Hercules, CA) as described previously (19) . The nitrocellulose was blocked for 60 rain at room temperature in 10 mM Tris-HCl, pH 8, 150 mM NaC1, 0.1% (vol/vol) Tween 20 (TBST) containing 5 % milk powder or 2 % BSA (Sigma Chemical Co.) when phosphotyrosyl proteins were analyzed. Immunodetection was performed with different antibodies as indicated in the figures. Antibody reaction was visualized using alkaline phosphatase-or peroxidase-conjugated secondary antibodies. Nitroblue tetrazolium salt and 5-bromo-4-chloro-3-indolylphosphate were used as reagents (Sigma Chemical Co.) for alkaline phosphatase; the ECL chemiluminescence system (Amersham International) was used for peroxidase. Quantification of the different bands was performed using a densitometric analyzer (CRIS, Ramonville, France), which determines the pixel volume in each area.
Overlay Assay
Total cytoskeletons isolated from thrombin-activated platelets (0.7 IU/ml for 5 rain) or immunopurifled p125 FAx were subjected to 5-15% gradient SDS-PAGE and blotted onto nitrocellulose. The nitrocellulose was incubated with 1% BSA, 1% milk powder in TBST (0.1% Tween 20) for 5 h and subsequently incubated overnight at 4°C in 50 mM Tris-HC1 (pH 7.5) containing 12 mM 2-mercaptoethanol, 0.2 M NaC1, and 0.1% milk powder in the presence of GST-p85t~-SH3, GST-p85a-SH2 (NH2), or GST (at 15 #g/ml). Nitrocellulose was then washed in TBST (0.1% Tween 20) containing 1% milk powder for 1 h to remove unbound material and then probed with anti-GST mAb as previously described.
Peptide Synthesis
The peptides KPPRPG, KVVRVG, and KPPRPG were prepared by solidphase synthesis on an automated peptide synthesizer (model 430A; Applied Biosystem Inc., Foster City, CA) according to N-tertbutyloxycarbonyl (t-Boc)-amino acids and symmetric anhydride or hydroxybenzotriazole ester as activation chemistry. The products were removed from the resin and simultaneously deprotected by reaction with liquid anhydrous hydrofluoric acid in the presence of anisol and m-cresol as a cation scavenger at -5°C. The purity of the final products (97%) was assessed by analytical reversephase liquid chromatography (column Aquapore RP 300, L8, 220 ram, 4.6 ram) and fast atom bombardment mass spectrometry (MH+, 651.2) on a ZAP-HS double focusing spectrometer (VG Analytical, UK).
Affinity Column
The proline-rich peptide from p125 ~Ar was coupled to CNBr-activated Sepharose 4B beads at a ratio of 4 nag of peptide per ml of activated beads according to the instructions provided by the manufacturer (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). Cytoskeletons were resuspended in 1 ml of lysis buffer as described for the immunoprecipitation method, precleared with Sepharose 4B, and incubated or not in the presence of a mixture of two different mAbs to the SH3 domain of p85~ (obtained from Dr. Waterfieid's Laboratory and Dr. Matsuda). 50/zl of 10% (wt/vol) beads coupled to the peptide were added during 120 min at 4°C. The beads were then washed three times as described for the immunoprecipitation method, resuspended in sample buffer, and separated by SDS-PAGE (7.5%). Proteins were transferred to nitrocellulose and probed with antibodies to p85c~.
Assay of Ptdlns 3-Kinase in the Presence of the Proline-rich Peptide from p125 Fax
PtdIns 3-kinase was immunopurified from the Triton X-100-sohlble fraction of resting platelets and was assayed essentially as previously described except that the final concentration of ATP was 50/~M and the exogenous lipid vesicles used were 150 t~M phosphatidylinositol 4-monophosphate/ 300 #M phosphatidylserine or 150 #M phosphatidylinositol/300 I~M phosphatidylserine. After addition of the peptide (solubilized in 50 mM Tris-HCI, pH 7.4), samples were preincubated for 10 rain at 4°C. The reaction was then started by adding 10 ttCi of [3,-32P]ATP and was performed at 37°C with shaking for 5 rain. The lipids were immediately extracted, analyzed, and quantified by HPLC (41) . Under these assay conditions, PtdIns(3)P or Ptdlns(3,4)P2 formation was linear with time for 10 rain.
Results
Ptdlns(3,4)Pz but Not PtdIns(3,4,5)Pj Synthesis Parallels Translocation of Activated Ptdlns 3-Kinase to the Cytoskeleton
We and others have previously shown that upon thrombin stimulation, both p85~ and PtdIns 3-kinase activity significantly relocate to the cytoskeleton of human platelets (18, 50). Quantitative immunoblotting (Fig. 1) showed that under resting conditions, p85ot was hardly detectable in the cytoskeleton, whereas up to 29 :t: 9% was translocated to this compartment after 5 rain of activation using 0.7 IU/ml thrornbin. A parallel decrease in the Triton X-100-soluble fraction was observed. The use of a highly specific antibody from Dr. Waterfield's laboratory unambiguously identified platelet p85 as the ot isoform (data not shown).
In agreement with Zhang et al. (50) , when PtdIns 3-kinase was assayed in the homogenate and in the cytoskeleton obtained from thrombin-stimulated cells, its specific activity (picomoles per minute per p85c0 was increased by eightfold in the cytoskeleton.
To investigate further a possible functional role for the relocation of PtdIns 3-kinase, we checked whether the kinetics of the production of D3-phosphorylated pbosphoinositides were correlated with the redistribution of the enzyme. Interestingly, Fig. 2 shows a striking correlation between PtdIns-(3,4)P2 accumulation in whole platelets, increasing PtdIns 3-kinase activity in the cytoskeleton, and translocation of p85ct to the cytoskeleton (Fig. 2, A , B, and C, respectively).
In contrast, the PtdIns(3,4,5)P3 signal (Fig. 2 A, inset) appeared to be more rapid than PtdIns(3,4)P2 synthesis, as previously reported (24, 38) . Thus, the accumulation of PtdIns(3,4)P2 but not of PtdIns(3,4,5)P3 temporally correlated with the translocation of PtdIns 3-kinase to the cytoskeleton.
~rosine Phosphorylation, Integrin Engagement, and Aggregation Are Required for Association of Ptdlns 3-Kinase with the Cytoskeleton and for Ptdlns(3,4)P2 Accumulation
Thrombin-induced platelet aggregation is accompanied by a number of biochemical events, among them pp6(Y-" translocation to the cytoskeleton, tyrosine phosphorylation of several cytoskeletal proteins, and actin polymerization. Fig. 3 , A and B show that translocation of p85c~, pp60~-"% and p125 FAr correlated well and may be considered late events, since they were significantly detectable only after 30 s of stimulation. In addition, Fig. 3 B indicates that translocation of p85ct, p125 rag, and pp60 ¢-'~ to the cytoskeleton was not due to an artifactual trapping of proteins during actin polymerization, which was very rapidly measurable. Indeed, the F-actin content increased about two times within 10 s of stimulation. Moreover, it is noteworthy that p85a, p125 ear, and pp60 ~-s' relocalization was significantly measurable only when 25% of aggregation (AT max%) was reached.
The tetrapeptide RGDS and tyrphostin AG-213 are commonly used to inhibit the binding of fibrinogen to integrin Ct,lb//33 receptor and to inhibit tyrosine phosphorylation, respectively. Both compounds have been previously shown to reduce significantly aggregation as well as PtdIns(3,4)P2 accumulation induced by thrombin (19, 42) . Here, we show that tyrphostin (Fig. 4 A) and RGDS (Fig. 4 B) were able to inhibit both the translocation of p85o~ to the cytoskeleton and Ptdlns(3,4)P2 synthesis (Table I) , with RGDS being somewhat more potent. The translocation of pp60 '-'~ has already been shown to depend on anb//~3 mobilization (22, 30) ; therefore, we used it as an internal control. Its relocalization was also clearly inhibited by RGDS (Fig. 4 B) , whereas tyrphostin had a clear but weaker inhibitory effect. Table I indicates that the percentage of inhibition of aggregation (AT max %) induced by tyrphostin or RGDS varied in the same way as the percentage of inhibition of p85, translocation to the cytoskeleton, as well as the percentage of inhibition of PtdIns(3,4)P2 accumulation. However, RGDS again had a more pronounced effect on aggregation. Moreover, EGTA (5 raM) was also able to inhibit thrombininduced aggregation by 80 + 3 %, and interestingly, p85o~ relocalization and Ptdlns(3,4)P2 synthesis were both inhibited in the same range (85 5:5 %). Finally, the absence of shaking during thrombin stimulation abolished these events by about the same percentage as the inhibition observed with EGTA, clearly indicating that they are aggregation dependent. Therefore, integrin engagement, aggregation, and tyrosine phosphorylation are crucial for Ptdlns(3,4)P2 accumulation as well as p85o~ translocation to the cytoskeleton. To investigate these relationships further, we have immunopurified the phosphotyrosyl proteins from the cytoskeleton and probed them with anti-p85t~ and anti-pp60 ¢-,'~ antibodies. Interestingly, both proteins were absent in the pool of phosphotyrosyl proteins obtained from the cytoskeleton of resting cells, whereas they were clearly detected in the immunoprecipitates obtained from the cytoskeleton of thrombin-actirated platelets (Fig. 5) . Again, this was inhibited in the presence of tyrphostin. An interesting question then concerned the tyrosine phosphorylation state of cytoskeletal p85c~.
Cytoskeletal Acamted Ptdlns 3-Kinase Is Not 13~osine Phosphorylated on p85~
Anti-p85a immunoprecipitates were prepared from the cytoskeleton of resting or thrombin-activated platelets. The presence of p85ot in such immunoprecipitates was analyzed by PtdIns 3-kinase assay and Western blotting (Fig. 6 A) . Both PtdIns 3-kinase activity and p85c~ were clearly detected in the anti-p85 immunoprecipitate obtained from the tyroskeleton of activated platelets (Fig. 6 A) , indicating the validity of the procedure. When these immunoprecipitated proteins were then probed with an anti-phosphotyrosine mAb ( Fig. 6 A, right panel) , we found that p85ce present in the cytoskeleton of activated platelets was itself virtually not tyrosine phosphorylated. However, possibly only a small population of p85oe is phosphorylated. Obviously, the best candidate would be p85ot recovered in the anti-phosphotyrosine immunoprecipitate obtained from the cytoskeleton of thrombin-stimulated platelets. To check this possibility, we first estimated, using nonlimiting amounts of antibody, the p85a content recovered in the anti-phosphotyrosine immunoprecipitate from the cytoskeleton of activated platelets ( Fig. 6 B, lane 2) compared with the content of p85a recovered in the anti-p85ce immunoprecipitate from a similar cytoskeleton (Fig. 6 B, lane 1 ) . The data indicate that only a subpopulation of p85ce was recovered in the anti-phosphotyrosine immunoprecipitate. Finally, when the immunopurified phosphotyrosyl proteins were then probed with an anti-phosphotyrosine antibody (Fig. 6 B, lane 3) , no 85-kD band could be detected, indicating that, after a 5-min stimulation, the pool of p85ct recovered in the anti-phosphotyrosine immunoprecipitate was virtually not tyrosine phos- phorylated. These data raised the question of the identification of the proteins interacting with Ptdlns 3-kinase in the cytoskeleton.
Translocation of Ptdlns 3-Kinase Is Directed to the Actin l~lament System
As a first attempt to localize Ptdlns 3-kinase in the cytoskeleton, we performed a selective extraction procedure. By solubilizing cytoskeleton in potassium iodine followed by in vitro polymerization of actin as previously described (32), we selectively obtained the actin filament system consisting of actin and actin-binding proteins. As indicated in Fig. 7 , actin was indeed present in these fractions, with a significant increase in F-actin content upon thrombin stimulation. As shown in Fig. 7 , p85t~ was hardly detectable in the F-actinrich fraction obtained from resting platelets, whereas in thrombin-activated platelets, p85c~ was clearly present in the F-actin fraction. Interestingly, p125 par and pp6(? -s'~ were also strongly present in this fraction (Fig. 7) . Finally, a significant PtdIns 3-kinase activity was measured in the isolated actin filamental system of stimulated cells (Fig. 7) , indicating that both p85t~ and the catalytic subunit pll0 were associated with actin or with an actin-binding protein in stimu- lated platelets. Moreover, this result shows that PtdIns 3-kinase was still able to bind to the actin filament system after one cycle of depolymerization-repolymerization of actin in vitro. These data do not prove a direct association of Ptdlns 3-kinase with actin, since several proteins may be candidates to link this enzyme to the actin filament system. Our previous data suggested an association of p85ot with a cytoskeletal tyrosine-phosphorylated protein; pp60 ~-s' is a possible candidate (20) . A 125-kD protein is also strongly recognized by anti-phosphotyrosine antibodies in the cytoskeleton of activated platelets (Fig. 6 B, lane 3) . Since platelet aggregation induces focal contact-like areas, p125 wx may thus be a good candidate as well (36) . Therefore, we investigated the possible interactions between Ptdlns 3-kinase and these two non-receptor tyrosine kinases.
Cytoskeletal Ptdlns 3-Kinase Is Associated with ~rosine-Phosphorylated p125 vax
Despite the use of various antibodies and methodologies, we were unable to demonstrate the presence of pp60 ~-''r in the anti-p85c~ immunoprecipitate (or the other way around) obtained from cytoskeleton (data not shown). Thus, we have no evidence for a direct interaction between Ptdlns 3-kinase and pp60 ,-sr~ in the cytoskeleton of activated platelets. We then prepared anti-p125 rAK immunoprecipitates from the cytoskeleton of resting and thrombin-stimulated platelets. They were probed with anti-phosphotyrosine and antip85ot antibodies. Fig. 8 shows that p125 vA~ present in the cytoskeleton of resting platelets was weakly phosphorylated, whereas significant tyrosine phosphorylation was observed upon thrombin stimulation. It is noteworthy that a protein of ,'~190 kD was also recognized and may be a putative p125rAX-binding phosphotyrosyl protein or a member of the focal adhesion complex. When anti-p85ot antibody was used as a probe, no signal appeared in the anti-p125 tax immunoprecipitate obtained from the cytoskeleton of resting platelets, whereas a clear and single 85-kD protein was detected upon thrombin stimulation. These data indicate a thrombindependent physical interaction between the regulatory subunit (p85ot) of Ptdlns 3-klnase and the tyrosine-phosphorylated p125 FAx in the cytoskeleton of activated platelets. This interaction appears specific, since under similar conditions, p85a was not recovered when nonimmune IgG1 from mouse was used instead of the anti-p125 wx antibody (Fig. 8,  lane C) . Moreover, in agreement with our previous data (Fig. 6) , the cytoskeletal p125rAX-associated p85ot was virtually not tyrosine phosphorylated, since no 85-kD protein was revealed in the anti-p125 tax immunoprecipitate with the anti-phosphotyrosine antibody (Fig. 8, left panel) .
Interaction of a Proline-rich Sequence of p125 FAr (706-711) with the SH3 Domain of p85a as a New Mechanism of Ptdlns 3-Kinase Activation
To determine the domain of interaction between p125 FAK and p85c~, we first investigated the potential binding of the SH2 domain of p85ot to the tyrosine-phosphorylated region of p125 FAx. Using the immobilized p85o~-SH2 (NH2) domain, we were unable to precipitate p125 rat significantly. More- Figure 7 . Association of p85c~ with the actin filament system. Proteins of the F-actin-rich fraction corresponding to 8 x l0 s resting or activated-platelets were separated by SDS-PAGE (7.5%), and analyzed by Western blotting. The presence of actin, p85~, p125 tax, and pp61Y -sr~ was checked using specific antibodies as indicated above each panel. over, overlay technique did not indicate binding of GSTp85o~-SH2 (NH2) to the immunopurified tyrosine-phosphorylated p125 tax on nitrocellulose (data not shown). These negative data are in agreement with the fact that p125 ear does not possess the typical consensus p85-SH2 binding domain in the potential tyrosine phosphate-containing sequence found near its catalytic domain.
Another possibility was the binding of a proline-rich domain of p125 FAx to the SH3 domain of p85ct. We therefore synthesized a peptide, KPPRPG, corresponding to a prolinerich sequence of human p125 F~r (residues 706-711). Once immobilized on Sepharose beads, this peptide could significantly bind cytoskeletal p85t~ (Fig. 9) . This direct interaction seems to be specific, since PLC-y1, another SH3-containing enzyme of the phosphoinositide metabolism present in platelets, was not found to bind to this peptide (data not shown). In addition, preincubation of resuspended cytoskeleton, obtained from activated platelets, with specific antibodies directed to the SH3 domain of p85t~ significantly prevented this association (Fig. 9, A and B, lane 3) , strongly suggesting that the proline-rich sequence of p125 ~Ar (701-711) interacts with the SH3 domains of p85ot. As a control, unrelated antibodies (nonimmune IgG1 from mouse or mAbs directed against the EGF receptor, which is not present in platelets) used instead of anti-p85tx-SH3 antibodies were not able to reduce the association significantly (data not shown). Moreover, Fig. 9 C shows that the p85o~-SH3 domain used as GST-p85t~-SH3 was also able to bind directly to the peptide KPPRPG in vitro NH2. Fig. 10 A indicates that p85~-SH3 but not p85c~-SH2 (NH2) was able to bind in vitro to the immunopurified p125 tax obtained from cytoskeleton of activated platelets. Since weak interactions may be favored in these experiments, we have done overlay assay in which blots of immunopurified p125 F~K (Fig. 10 B,  lane 1 
conditions, p85a-SH3 was able to bind to immunopurified p125 rat (Fig. 10 B, lane 1) and to a 125-kD protein of the cytoskeleton of activated platelets that matches p125 F~ (Fig. l0 B, lane 3) . In addition, p85ot-SH3 was found to bind more weakly to three other proteins (Fig. 10 B, lane 3) of "o93, 64, and 68 kD, which have yet to be identified.
Finally, we assessed the effect of the binding to p85t~ of the proline-rich sequence of p125 rat on PtdIns 3-kinase activity. As shown in Fig. 11 , the peptide KPPRPG significantly increased the PtdIns 3-kinase activity of immunopurified enzyme by 2.5-fold. Half-maximal activation was obtained in the presence of 10/zM peptide. Preincubation of the enzyme with antibodies directed to the SH3 domain of p85a before addition of the peptide reduced this activation by ,o40% (data not shown). Finally, a control peptide, KVVRVG (Fig.  11) or KPPRVG (data not shown), was unable to activate PtdIns 3-kinase significantly under similar conditions.
To prove definitively that the direct binding of the peptide is responsible for the activation of PtdIns 3-kinase, we preincubated the immunopurified enzyme with or without 50/zM peptide for 120 rain in lysis buffer lacking SDS, washed the immunocomplex twice to remove the unbound peptide, and finally assayed for PtdIns 3-kinase. Again, a twofold increase in activity was observed, indicating that the direct binding of the peptide is responsible for the activation of PtdIns 3 -kinase.
Discussion
In agreement with Zhang et al. (50) likely accompanied by a functional pll0 catalytic subunit, since Ptdlns 3-kinase activity was measured in the cytoskeleton of activated platelets and exhibited a higher specific activity than in the homogenate. Interestingly, Ptdlns(3,4)P2 but not PtdIns (3, 4, 5) P3 synthesis paralleled the translocation of both p85ot and Ptdlns 3-kinase activity to the cytoskeleton, strongly suggesting a relationship between these two events. In thrombin-stimulated platelets, PtdIns (3, 4, 5) P3 is produced very rapidly, whereas Ptdlns(3,4)P2 accumulates at a later stage (24, 38) . Although Ptdlns(3,4)P2 has been shown to be a degradation product of Ptdlns(3,4,5)P3 in neutrophils, Sorisky et al. (38) have demonstrated that the production of these two phospholipids is regulated differently in thrombin-stimulated platelets. In this model, in contrast to the Ptdlns(3,4)P2 response, the accumulation of Ptdlns (3, 4, 5) P3 is unaffected by Ca 2÷ or the tetrapeptide RGDS (38, 42) . Our results suggest that the redistribution of Ptdlns 3-kinase to the cytoskeleton may be of importance for the accumulation of Ptdlns(3,4)P2. Detailed time course studies of Ptdlns(3,4)P2 accumulation and Ptdlns 3-kinase, p125 me, and pp60 ~-'~ relocalization revealed that these events are in fact concomitant and significantly detectable only when 25-30% of aggregation (AT max %) is reached. Similar data have been obtained by Torti et al. (45) for the low molecular weight GTP-binding protein Rap2B.
In contrast, actin polymerization is very rapidly detected, since double the amount of F-actin is observed within 10 s of stimulation. One may note that this time course of polymerization fits rather well with the Ptdlns(3,4,5)P3 signal as previously shown in fMLP-stimulated neutrophils (9) . Moreover, it is noteworthy that the state of actin polymerization may in turn influence the phosphorylation state of several cytoskeletal proteins, including the focal adhesion kinase p125 FAr (23) .
On the other hand, we have previously shown that PtdIns(3,4)P2 accumulation is inhibited by RGDS (42) . Here we demonstrate that the redistribution of p85ot to the actin cytoskeleton and aggregation (AT max %) are inhibited in a similar manner by RGDS. In addition, EGTA (5 raM) Figure I0 . Direct binding of p85c~-SH3 to cytoskeletal p125 pax. p125 F~r was immunopurified from cytoskeleton of thrombin-activated platelets (0.7 IU/ml for 5 min) as described in Materials and Methods. The immunocomplex was then incubated in lysis buffer at 4"C for 1.5 h in the presence of 15 t~g/ml GST-pg5c~-SH3, GST-p85c~-SH2 (NH2), or GST alone, as indicated in the figure. After two washes in lysis buffer and three washes in 50 mM Tris-HCI, pH 7.35, 150 mM NaC1, the adsorbed proteins were analyzed by Western blotting using the anti-GST antibody as a probe (,4). (B) Immunopurified p125 ~a~ 0ane 1) or total cytoskeletal proteins prepared from activated platelets (lanes 2 and 3) were resolved by 7.5 % or 5-15 % SDS-PAGE, respectively, and blotted onto nitrocellulose for overlay assay as indicated in Materials and Methods. Proteins on nitrocellulose were then probed with GST-pg5cz-SH3 (lanes 1 and 3) or with GST alone (lane 2) and subsequently detected with anti-GST antibody using the ECL system. The nitrocellulose of lane 3 has then been stripped according to the procedure provided in the ECL kit and reprobed with the anti-p125 Far antibody. The position of p125 FAr is indicated by the arrowhead. or the absence of shaking during activation significantly inhibited the association ofp85a with the cytoskeletons as well as the accumulation of Ptdlns(3,4)P2. Therefore, aggregation via the binding of adhesive proteins to their receptors, especially fibrinogen binding to andl3~, is required for both the production of Ptdlns(3,4)P2 and the translocation of Ptdlns 3-kinase and pp60 c-'~ to the actin cytoskeleton. The similarity both in the time course and in the sensitivity of tyrphostin and RGDS of Ptdlns(3,4)P2 synthesis and Ptdlns 3-kinase translocation to the cytoskeleton suggests that these events might be tightly linked. This is not the case for Ptdlns(3,4,5)P3 production, which is not regulated in the same way (38, 48) . Such a difference would be explained by the presence in human platelets of a Ptdlns 3-kinase activated by G-protein By subunits (44) , which was recently identified in other hematopoietic cells (39) . Our present data and those previously obtained on Glanzmann's thrombastenic platelets (42) may suggest a role for the etnb//33-1inked actin cytoskeleton in the compartmentalization of activated Ptdlns 3-kinase. The inhibitory effect of tyrphostin that we observed is in agreement with the fact that when RGDS blocks the binding of fibrinogen and other ligands to at~b/B3, thrombininduced tyrosine phosphorylation of several substrates is also blocked (11, 17) . The chronology of this cascade of events may also explain why RGDS has a more potent inhibitory effect than tyrphostin. Thus, both fibrinogen binding to ot~,b/B3 and the subsequently induced tyrosine phosphorylations are crucial events for the translocation of Ptdlns 3-kinase to the actin cytoskeleton and the production of Ptdlns(3,4)P2 in thrombin-stimulated platelets. The role of tyrosine kinases in this mechanism is confirmed by the presence of a fraction of p85tx in anti-phosphotyrosine immunoprecipitates obtained from the cytoskeleton of thrombinactivated platelets. However, we have found that the pool of cytoskeletal p85o¢ is virtually not tyrosine phosphorylated, even though only a subpopulation of p85ct is recovered in the anti-phosphotyrosine immunoprecipitate. Furthermore, we were also unable to show the tyrosine phosphorylation of p85o~ in the Triton X-100-soluble fraction of activated platelets (data not shown). Therefore, its presence in the pool of phosphotyrosyl proteins is possible only if p85ct is physically associated with another tyrosine-phosphorylated protein. This result stimulated us to investigate the proteins that may interact with Ptdlns 3-kinase in the cytoskeleton of activated platelets. We found that the relocalization of Ptdlns 3-kinase and pp60 .... is preferentially directed to the actin filament system consisting of F-actin and actin-binding proteins. Functional Ptdlns 3-kinase is still able to bind to the actin filaments even after one cycle of depolymerizationrepolymerization of actin in vitro. Our observations are consistent with the recent data obtained by Fox et al. (13) . These authors have observed that the Triton X-100-insoluble membrane skeleton components sedimented at 100,000 g, such as spectrin, vinculin, or talin, as well as pp60 ..... , pp62¢-y% and p21='-GAP, are redistributed to the Triton X-100-insoluble low speed fraction (15,000 g) during thrombin-induced aggregation. In this respect, it is noteworthy that a number of proteins that have been identified in the platelet membrane skeleton are actin-binding proteins (12, 13) . Our data do not prove a direct association with actin, since actin-binding proteins may link Ptdlns 3-kinase to F-actin and since we found a population of cytoskeletal p85ct associated with a tyrosinephosphorylated protein. The kinase pp60 .... is found in the actin-rich fraction and has been described to interact weakly with Ptdlns 3-kinase in the Triton X-100-soluble fraction of thrombin-activated human platelets (20) . Therefore, we have investigated such a possibility in the cytoskeleton. However, using both Western blot and enzymatic assays, we have failed to find a clear interaction between Ptdlns 3-kinase and pp60 .... under our conditions (data not shown). The association between p85a and src-like kinases has been described in other models and seems to be due to SH3-mediated interactions (35) ; this mechanism might be minor in platelets (20) . However, another interesting candidate is p125 r~r, a protein tyrosine kinase involved with integrin signaling that is phosphorylated and activated upon thrombin stimulation of platelets (27) . Moreover, actin-dependent cytoskeletal interactions seem to be necessary for these events (27) . Interestingly, p125 e~x is not activated in platelets from Glanzmann's thrombasthenia (27) , which also fail to produce Ptdlns(3,4)P2 (42) . Our results show both the presence of a tyrosine-phosphorylated form of p125 ra~ in the cytoskeleton of thrombin-activated platelets and an interaction between tyrosine-phosphorylated p125 raK and non-tyrosine-phosphorylated p85a in this cytoskeleton. Furthermore, the amount of p85a found associated with p125 FAr is comparable to the amount of p85ot recovered in the anti-phosphotyrosine immunoprecipitate. This association may therefore explain the presence of non-tyrosine-phosphorylated p85a in such immunoprecipitates and the increase in its ability to be precipitated with the anti-phosphotyrosine antibody after thrombin stimulation. It is noteworthy that the potential tyrosine phosphate-containing domain found near the catalytic domain of p125 tax (1) does not exhibit the consensus motif known to bind the SH2 domain of p85a, and using different approaches, we were unable to demonstrate an association by this way. However, two proline-rich domains (564-576 and 694-714) containing the PPXP motif (6, 49) are found in the sequence of p125 rAK (1). Here we show that a peptide corresponding to residues 706-711 of human p125 rat binds to the SH3 domain of non-tyrosine-phosphorylated p85ct. This binding seems to be specific, since the p85ct SH3 domain was also able to bind to immunopurified p125 pA~ in vitro or to a 125-kD cytoskeletal protein that matches p125 rag on nitrocellulose.
Moreover, this binding led to a significant activation of Ptdlns 3-kinase. This activation possibly results from the induction of a conformational change leading to the activation of the p110 catalytic subunit, which is comparable to the activation described for Ptdlns 3-kinase by the tyrosinephosphorylated PDGF receptor (10), IRS-1 (28) and the src family kinase SH3 (34) . Our data strongly suggest a new mode of Ptdlns 3-kinase regulation in which binding of proline-rich sequence of p125 ra~ (706-711) to the SH3 domain of p85a increased enzymatic activity of this lipid kinase. This mechanism is operative during thrombin-induced aggregation and may be important for enzyme access to its substrate at very specific areas of the cell (i.e., focal contacts). The role of 3D-phosphorylated phospholipids at these particular points has now to be investigated in detail. However, with respect to the data published recently, it is possible to suggest that these lipids may play a role in the organization of actin polymerization, leading to the formation of actin filament bundles linked to focal contact points.
We propose that p125 r~ is responsible, at least in part, for the indirect binding of Ptdlns 3-kinase to actin microfilamerits and plays a critical role in activating and directing this lipid kinase to an appropriate location. Since we demonstrate here a role of aggregation, integrin receptor engagement and subsequent tyrosine phosphorylation in PtdIns 3-kinase translocation, and concomitant Ptdlns(3,4)P2 accumulation, it is tempting to suggest that p125 FA~c may be a key enzyme in coupling integrin receptor signaling with these events. During the reviewing process of this manuscript, Chen and Guan (4, 5) described an interaction of p125 rAK with Ptdlns 3-kinase in fibroblasts. Interestingly, this association was induced by cell adhesion to fibronectincoated culture dishes (5) or by PDGF treatment (4). Our results also suggest that Ptdlns 3-kinase likely displays different modes of interaction with cytosketetal elements since only o025 % of cytoskeletal p85o~ is found associated with p125 tax. This physical interaction may be transient, and Ptdlns 3-kinase may then be compartmentalized in other cytoskeletal areas possibly to be down-regulated. The presence of the SH2 and SH3 domains as well as SH3-binding motifs in the p85 subunit (25) may explain the different targeting of these associations. Further work is necessary to identify all of the different cytoskeletal proteins with which Ptdlns 3-kinase may be associated and their relevant biochemical and functional relationships.
In conclusion, focal contact-like areas induced upon thrombin stimulation of platelets, involving Ot~b/~3, p125 ~Ax, as well as other phosphotyrosyl proteins and actin microfilamerits, are very important for Ptdlns 3-kinase relocation and Ptdlns(3,4)P2 accumulation. Whether this inositol lipid may in turn play a role in stabilizing the clot remains to be established.
